Latest filing published 07 Feb 2018 for Neurocrine Biosciences INC, €100k.
Filing timeline
BuySaleInsider track record
Christopher Flint OBrien: trading record in brief
This profile gathers the share dealings of Christopher Flint OBrien in Neurocrine Biosciences Inc. Over a trading history stretching from 29 September 2008 to 6 February 2018, the count stands at 85 filings.
The open-market record consists of 64 sales worth €24.0M, with no purchase. Outside the open market, there are 1 share grant and 20 option exercises. So far in 2018, the count stands at no purchases and 3 sales.
Most recently, on 7 February 2018, the filings show an open-market sale worth €75k in Neurocrine Biosciences Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Christopher Flint OBrien
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 1,500 shares@ US$83.010.5% of flowCommon StockSEC:0001209191-18-008219:0
- 1,113 shares@ US$83.400.4% of flowCommon StockSEC:0001209191-18-008219:1
- 1,014 shares@ US$82.480.4% of flowCommon StockSEC:0001209191-18-008219:2
- 1,750 shares@ US$79.140.6% of flowCommon StockSEC:0001209191-18-004246:0
- 45,299 shares@ US$8.661.8% of flowCommon StockSEC:0001209191-17-059434:0
- 45,299 shares@ US$69.7114.5% of flowCommon StockSEC:0001209191-17-059434:1
- 7,518 shares@ US$8.650.3% of flowCommon StockSEC:0001209191-17-059434:2
- 7,518 shares@ US$69.712.4% of flowCommon StockSEC:0001209191-17-059434:3
- 6,925 shares@ US$8.650.3% of flowCommon StockSEC:0001209191-17-055457:0
- 6,925 shares@ US$61.041.9% of flowCommon StockSEC:0001209191-17-055457:1
- 52,817 shares@ US$8.662.0% of flowCommon StockSEC:0001209191-17-051944:0
- 52,817 shares@ US$57.5013.6% of flowCommon StockSEC:0001209191-17-051944:1
- 8,734 shares@ US$8.650.3% of flowCommon StockSEC:0001209191-17-046685:0
- 8,734 shares@ US$50.002.0% of flowCommon StockSEC:0001209191-17-046685:1
- 59,645 shares@ US$5.761.6% of flowCommon StockSEC:0001209191-17-034638:0
- 24,105 shares@ US$5.760.7% of flowCommon StockSEC:0001209191-17-034638:1
- 21,884 shares@ US$8.660.9% of flowCommon StockSEC:0001209191-17-034638:2
- 105,634 shares@ US$53.3227.0% of flowCommon StockSEC:0001209191-17-034638:3
- 12,861 shares@ US$50.413.2% of flowCommon StockSEC:0001209191-17-026884:0
- 204 shares@ US$51.230.1% of flowCommon StockSEC:0001209191-17-026884:1
- 1,206 shares@ US$43.170.3% of flowCommon StockSEC:0001209191-17-008912:0
- 1,500 shares@ US$42.500.3% of flowCommon StockSEC:0001209191-17-008131:0
- 1,750 shares@ US$40.660.4% of flowCommon StockSEC:0001209191-17-004301:0
- 1,750 shares@ US$43.350.4% of flowCommon StockSEC:0001209191-17-003588:0
- 25,000 shares@ US$52.846.6% of flowCommon StockSEC:0001209191-16-150474:0
25 of 76 declarations
